Skip to main content
SpringerLink
Log in

Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs

  • Original Article
  • CA, Nucleoside Transport Inhibitor, Synergism, Antitumor-Drug Activity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Antibiotic C3368-A (CA) is produced by a fungus strain from a soil sample collected in Antarctica. CA markedly inhibited radiolabeled thymidine and uridine transport in mouse Ehrlich carcinoma cells, its 50% inhibitory concentration (IC50) being 4.6 and 7.7 μM, respectively. In clonogenic assay, CA displayed a synergistic effect with methotrexate (MTX), mitomycin C (MMC), 5-fluorouracil (5FU), and Adriamycin (ADR) against human oral epidermoid carcinoma KB cells. CA also markedly enhanced the inhibitory effect of 5FU and ADR on the proliferation of human hepatoma BEL-7402 cells as determined by thep-nitrophenyl-N-acetyl-β-d-glucosaminide (NAG) enzyme-reaction assay. 5FU or ADR cytotoxicity was not augmented by CA in human fetal lung 2BS cells. In vivo, CA significantly potentiated the inhibitory effect of MMC against colon carcinoma 26 in mice. No significant augmentation of toxicity by the combination was found in treated mice. The results suggest that CA, the newly found nucleoside-tranport inhibitor, may be useful in potentiation of the effect of antitumor drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alberts DS, Einspahr J, Peng YE, Spears P (1987) Dipyridamole (D) potentiation of FUdR antitumor IIID-3 activity. Clin Pharmacol Ther 41:247

    Google Scholar 

  2. Baselga J, Magill GB, Curley T, Casper ES (1990) Phase II trial of PALA+dipyridamole in patients with metastatic soft tissue sarcoma. Proc Am Assoc Cancer Res 31:200

    Google Scholar 

  3. Budd GT, Jayaraj A, Grabowski D, Adelstein D, Bauer L, Boyett J, Bukowski, R, Murthy S, Weick J (1990) Phase I trial of dipyridamole with 5-fluorouracil and folinic acid. Cancer Res 50:7206

    Google Scholar 

  4. Buzaid AC, Alberts DS, Einspahr J, Mosley K, Peng YM, Tutsch K, Spears CP, Garewal HS (1989) Effects of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients. Cancer Chemother Pharmacol 25:124

    Google Scholar 

  5. Cao SS, Zhen YS (1989) Potentiation of anitmetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 24:181

    Google Scholar 

  6. Chan TCK, Young B, King ME, Taetle R, Howell SB (1985) Modulation of the activity of PALA by dipyridamole. Cancer Treat Rep 69:425

    Google Scholar 

  7. Chan TCK, Markman M, Pfeifle CE, Taetle R, Abramson I, Howell SB (1988) Uridine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 22:83

    Google Scholar 

  8. Cheng YQ, Qi CQ, Chen WJ (1992) Studies on antibiotics fromChrysosporium sp. strain C3368, one of the psychrophiles from Antarctica. II Isolation and structure determination of antibiotic C3368. Chin J Antibiot 17:404

    Google Scholar 

  9. Damon LE, Cadman EC (1986) Advances in rational combination chemotherapy. Cancer Invest 4:421

    Google Scholar 

  10. Fox M, Boyle JM, Kinsella AR (1991) Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer 64:428

    Google Scholar 

  11. Gingrich JR, Keane TE, Walther PJ, Duke U (1991) Disparate in vivo impact of the chemosensitizer dipyridamole on the therapeutic index of cisplatin, carboplatin, and etoposide. A preclinical evaluation using a human bladder cancer xenograft model. Proc Am Assoc Cancer Res 32:374

    Google Scholar 

  12. Goel R, Cleary SM, Horton C, Balis FM, Zimm S, Kirmani S, Howell SB (1989) Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. J Clin Oncol 7:2262

    Google Scholar 

  13. Higano CS, Livingston RB (1989) Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial. Cancer Chemother Pharmacol 23:259

    Google Scholar 

  14. Hirose M, Takeda E, Ninomiya T, Kuroda Y, Miyao M (1987) Synergistic inhibitory effects of dipyridamole and vincristine on the growth of human leukaemia and lymphoma cell lines. Br J Cancer 56:413

    Google Scholar 

  15. Howell SB, Hom D, Sanga R, Vick JS, Abramson IS (1989) Comparison of the synergistic potentiation of etoposide, doxorubicin and vinblastine cytotoxicity by dipyridamole. Cancer Res 49:3178

    Google Scholar 

  16. Hu JL, Li YY, Wang LP, Xue YC (1993) Biological characteristics and biological activity of soil microorganisms from Antarctic King George Island. Acta Microbiol Sin 33:151

    Google Scholar 

  17. Hughes JM, Tattersall MHN (1989) Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport. Br J Cancer 59:381

    Google Scholar 

  18. Jekunen A, Vick J, Sanga R, Chan TCK, Howell SB (1992) Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res 52:3566

    Google Scholar 

  19. Keane TE, Rosner G, Donaldson JT, Norwood DL, Poulton SH, Walther PJ (1990) Dipyridamole-cisplatin potentiation:enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. J Urol 144:1004

    Google Scholar 

  20. Kusumoto H, Maehare Y, Anai H, Kusumoto T, Sugimachi K (1988) Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo. Cancer Res 48:1208

    Google Scholar 

  21. Landergren U (1984) Measurement of cell numbers by means of the endogenuous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods 67:379

    Google Scholar 

  22. Mouwerik TJV, Pangallo CA, Willson JKV, Fischer PH (1987) Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol 36:809

    Google Scholar 

  23. Moyer JD, Oliver JT, Handschmacher RE (1981) Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res 41:3010

    Google Scholar 

  24. Nelson JA, Drake S (1984) Potentiation of methotrexate toxicity by dipyridamole. Cancer Res 44:2493

    Google Scholar 

  25. Newell DR, O'Connor PM, Calvert AH, Harrap KR (1986) The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of [3H]thymidine in the rat. Biochem Pharmacol 35:3871

    Google Scholar 

  26. Schwartz PM, Milstone LM (1989) Dipyridamole potentiates the growth-inhibitory action of methotrexate and 5-fluorouracil in human keratinocytes in vitro. J Invest Dermatol 93:523

    Google Scholar 

  27. Seeger J, Woodcock TM, Lalley KA, Wieman TJ (1988) Reduction of hepatotoxicity from intraarterial 2′, 5-fluorodexoyuridine (FudR) by dipyridamole (DP). Proc Am Assoc Cancer Res 29:351

    Google Scholar 

  28. Shalinsky DR, Andreeff M, Howell SB (1990) Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res 50:7537

    Google Scholar 

  29. Shalinsky DR, Slovak ML, Howell SB (1991) Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdrl expression. Br J Cancer 64:705

    Google Scholar 

  30. Sobrero AF, Bertino JR (1985) Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line. Cancer Treat Rep 69:279

    Google Scholar 

  31. Weber G (1983) Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture. Cancer Res 43:3466

    Google Scholar 

  32. Weber G, Jayaram HN, Pillwein K, Natsumeda Y, Reardon MA, Zhen YS (1987) Salvage pathoways as targets of chemotherapy. Adv Enzyme Regul 26:335

    Google Scholar 

  33. Zhen YS, Lui MS, Weber G (1983) Effects of acivicin and dipyridamole on hepatoma 3924A cells. Cancer Res 43:1616

    Google Scholar 

  34. Zhen YS, Cao SS, Xue YC, Wu SY (1991) Green tea extract inhibits nucleoside transport and potentiates the antitumor effect of antimetabolites. Chin Med Sci J 6:1

    Google Scholar 

  35. Zhen YS, Taniki T, Weber G (1992) Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. Oncol Res 4:73

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tiantan, 100050, Beijing, China

    Jian Su, Yong-su Zhen, Chang-qing Qi & Ji-lan Hu

Authors
  1. Jian Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong-su Zhen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang-qing Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ji-lan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Su, J., Zhen, Ys., Qi, Cq. et al. Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs. Cancer Chemother. Pharmacol. 36, 149–154 (1995). https://doi.org/10.1007/BF00689200

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689200

Key Words

Search

Navigation